TL;DR: The core question behind stopping GLP-1 and weight regain (do you take them forever) has a clear evidence-based answer: in the trials, most people regain roughly half to two-thirds of their lost weight within a year of full withdrawal, because obesity physiology reasserts itself. Continued or lower maintenance dosing preserves results far better than stopping cold.
Why “do you take GLP-1s forever” is the wrong question
The phrasing that fills forums and subreddits is understandable but slightly off. GLP-1 receptor agonists like semaglutide and tirzepatide were not designed as a course of antibiotics you finish and forget. They are studied and increasingly framed as ongoing treatments for a chronic, relapsing condition. In December 2025 the World Health Organization issued its first guideline on GLP-1 medicines and described obesity explicitly as a chronic, progressive, and relapsing disease.
So the honest reframing is this: you do not necessarily need the same starting dose forever, but the physiology that made you gain weight does not disappear because a scale reads lower. The real topic of stopping GLP-1 and weight regain (do you take them forever) is about how much of your result you keep, and what a realistic long-term plan looks like, not whether the drug is magic.
Set point biology is the reason. When you lose fat, your body reads it as a threat and defends the old weight. Circulating leptin falls, the hunger hormone ghrelin rises, resting metabolic rate drops slightly for your new size, and satiety signalling weakens. GLP-1 medications quiet that counter-attack while you take them. Remove the medication and the counter-attack resumes, often asymmetrically: appetite climbs while energy expenditure stays suppressed.
What the research shows about stopping GLP-1s
Three randomized trials do most of the heavy lifting here. Read together, they tell a consistent story about regain and about maintenance.
STEP-1 extension: full withdrawal of semaglutide
In the STEP-1 trial, adults with obesity lost a mean 17.3% of body weight over 68 weeks on semaglutide 2.4 mg plus lifestyle support. In the extension study, both the drug and the lifestyle programme were stopped. One year later, at week 120, participants had regained about two-thirds of their lost weight, ending at a net loss of roughly 5.6% from baseline. Cardiometabolic gains in blood pressure, lipids and glycaemia drifted back toward starting values too. This is the cleanest published picture of cold-turkey discontinuation.
Mean body-weight loss from baseline. Drug + lifestyle stopped at week 68; measured again at week 120.
STEP-4: continuing versus switching to placebo
STEP-4 isolated the medication’s role. Everyone reached the semaglutide 2.4 mg maintenance dose by week 20, then was re-randomized either to continue or to switch to placebo. From week 20 to 68, continuers lost a further 7.9%, while those switched to placebo regained 6.9%. Same people, same lifestyle programme, opposite trajectories, the drug being the only difference.
SURMOUNT-4: the tirzepatide withdrawal data
SURMOUNT-4 ran the same design with tirzepatide. After a 36-week lead-in producing a striking 20.9% mean weight loss, participants were randomized to continue or stop. Over the following year, continuers lost an additional 5.5%, while those switched to placebo regained 14% on average, a net gap near 19–20 percentage points. Nearly 90% of continuers kept at least 80% of their weight loss, versus about 17% of those who stopped.
A 2025 systematic review and meta-analysis in eClinicalMedicine pooled 18 randomized trials and roughly 3,771 participants and found discontinuation produced a mean rebound of about 5.63 kg, with regain typically beginning around 8 weeks after stopping and plateauing near 20–26 weeks. The literature is overwhelmingly human randomized trial data here, not animal extrapolation, which is unusually strong for this field.
Regain by the numbers
The table below summarizes what each pivotal trial actually reported. These are trial-average figures in people with obesity, not individual guarantees.
| Trial | Drug | Peak loss | What was stopped | Result after ~1 year |
|---|---|---|---|---|
| STEP-1 extension | Semaglutide 2.4 mg | 17.3% | Drug + lifestyle | Regained ~2/3; net ~5.6% loss |
| STEP-4 | Semaglutide 2.4 mg | ~10.6% by wk 20 | Drug only (to placebo) | Placebo group regained 6.9% |
| SURMOUNT-4 | Tirzepatide | 20.9% | Drug only (to placebo) | Placebo regained ~14% |
| Meta-analysis (2025) | Various GLP-1 | varies | Drug | Mean rebound ~5.63 kg |
The pattern is remarkably stable: stopping GLP-1 and weight regain (do you take them forever) is not a coin flip. On average, meaningful regain is the expected outcome of full withdrawal, though a minority of people do hold their loss better than the mean, and lifestyle scaffolding matters at the margins.
Drug-only randomized comparisons: STEP-4 (semaglutide) and SURMOUNT-4 (tirzepatide)
The maintenance dose idea: a realistic middle path
“Forever on the max dose” is a false choice that the data does not actually demand. What the evidence supports is continued exposure, and there is growing interest in whether that exposure can be smaller or less frequent once you reach goal.
- Lower standing dose. Many clinicians step patients down from a weight-loss dose to a lower maintenance dose once the target is reached, aiming to hold results with less drug. This is the same logic behind a structured GLP-1 microdosing guide for 2026, where smaller amounts are studied for tolerability and maintenance rather than maximal loss.
- Reduced frequency. A 2025 Obesity paper and Obesity Week data explored less-frequent dosing, for example every two weeks, as a maintenance strategy. Early signals are encouraging but the studies are small and not yet definitive.
- Distinguish a plateau from an endpoint. Hitting a stall on the drug is normal biology, not a signal to quit. If your loss has flattened, the fix usually lives inside your current protocol, which is exactly what our GLP-1 weight-loss plateau breakdown addresses, rather than in stopping.
The candid caveat: robust head-to-head trials proving that a specific low maintenance dose holds weight as well as the full dose are still thin. Continued treatment is the best-evidenced maintenance approach today; de-escalation is promising and reasonable but under-studied. Compound reference pages such as semaglutide 10mg and tirzepatide 10mg exist for research-context education, not as a dosing prescription.
Making the result last
Whatever the dose plan, the same levers that build weight loss also protect it. Preserving lean mass with adequate protein and resistance training keeps resting metabolism higher, which is why avoiding muscle loss is worth real attention. Sleep, alcohol, NEAT (non-exercise movement) and food environment all push on the defended set point. None of these replace the medication’s effect in the trials, but they widen the gap between the average outcome and the best outcomes.
The mindset shift that matters most: treating obesity like the chronic, relapsing condition the WHO and the trial evidence describe. That framing turns “do I take this forever” into “what is the smallest sustainable plan that keeps my result,” which is a far more answerable question.
Frequently Asked Questions
How much weight should I realistically expect to lose per week or month?
Trial averages work out to roughly 0.3 kg per week for semaglutide and slightly more for tirzepatide, but loss is front-loaded, so early weeks feel faster. Over a full year, semaglutide averaged about 14% and tirzepatide about 16–20% of body weight in pivotal trials.
What happens to my weight when I come off tirzepatide?
In SURMOUNT-4, participants who stopped tirzepatide regained roughly 14% of body weight over the following year, while continuers lost a further 5.5%. Only about 17% of those who stopped kept at least 80% of their loss, versus nearly 90% who continued. Regain typically begins within about 8 weeks.
How low can I go on a maintenance dose and still keep it off?
Honestly, the evidence is not settled. Clinicians often step down to a lower maintenance dose, and early studies test less-frequent dosing such as every two weeks. Continued treatment is the best-proven strategy today; the minimum effective maintenance dose is still being researched and likely varies between individuals.
Is regain after stopping inevitable?
Not absolutely, but it is the statistical default. Across trials, most people regain about half to two-thirds of their loss within a year of full withdrawal because appetite hormones and a defended set point reassert. A minority hold results better, and strong lifestyle habits plus some continued treatment tilt the odds meaningfully.
References
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48.
- Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine. 2025.
- Wu V, et al. Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy. Obesity. 2025.
- World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. December 2025.
For research and educational use only. This article summarizes published literature and is not medical advice or a human-dosing recommendation.